Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with Acute Myeloid Leukemia.

Shalaka Hampras(Moffitt Cancer Center), Kirsten B. Moysich(American Cancer Society), Meir Wetzler, Joli Weiss(Translational Genomics Research Institute), Maria R. Baer(University of Maryland, Baltimore), Gary Zirpoli(Roswell Park Comprehensive Cancer Center), LaurieAnn Ford, Javier G. Blanco(Biomedical Research Institute), Prashant K. Singh, Lara Sucheston(Roswell Park Comprehensive Cancer Center), Raj Chennamaneni
PubMed
January 1, 2010
Cited by 45

Related Papers

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Type I and II Endometrial Cancers: Have They Different Risk Factors?
|Journal of Clinical Oncology|2013|833
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
|The Lancet Oncology|2017|493